Company Overview and News
LISLE, Ill., May 18, 2018 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS) announced the retirement of Walter Catlow yesterday at its Annual Shareholders Meeting. Kieran O’Sullivan, Chairman and CEO, and Bob Profusek, CTS’ Lead Independent Director, expressed their sincere gratitude to Mr. Catlow for his many years of outstanding service.
LISLE, Ill., May 17, 2018 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE:CTS) declared a cash dividend of $0.04 per share, payable July 27, 2018, to shareholders of record at the close of business on June 22, 2018.
WEST PALM BEACH, FL / ACCESSWIRE / May 8, 2018 / Alliance BioEnergy Plus, Inc. (OTCQB: ALLM) (the "Company") announced today that Dr. Anthony Santelli II (53) has been formally elected to fill an open seat on the Board of Directors by unanimous vote. In the same Board meeting Chairman and CEO Daniel de Liege nominated Board Member Gerry to take over the Chairmanship of the Company's Board. The motion passed by unanimous vote and Mr.
AMY CTS 4345 AMYZF ALLM
LISLE, Ill., April 24, 2018 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS) will be presenting at the Oppenheimer Industrial Growth Conference on Tuesday, May 8, 2018 at 10:15 AM EDT at the Westin New York Grand Central Hotel in New York City. This conference will focus on a variety of leading industrial growth companies. Additional information on the Oppenheimer Industrial Growth Conference is available at www.
WEST PALM BEACH, FL / ACCESSWIRE / April 23, 2018 / Alliance BioEnergy Plus, Inc. (OTCQB: ALLM) (the "Company") announced today that Gerry David (66) has been formally elected to fill an open seat on the Board of Directors by, unanimous vote. Company CEO Daniel de Liege said, "Mr. David brings a lot of experience in public company senior management and in commercializing new technologies and products, we're looking forward to his input and guidance.
CTS 4345 CELH ALLM
MONTRÉAL, April 19, 2018 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (the "Company" or "Siyata") (TSX-V:SIM) (OTCQX:SYATF), is pleased to announce that it has received all major industry and Government approvals including Federal Communications Commission (“FCC”) Google Android Compatibility Test Suite (“CTS”), PCS Type Certification Review Board (“PTCRB”), Conformité Européenne (“CE”) and Industry Canada (“IC”) for its Uniden® UV350 (“UV350”) device.
CTS 4345 SIM SYATF SIMFF
WEST PALM BEACH, FL / ACCESSWIRE / April 5, 2018 / Alliance BioEnergy Plus, Inc. (OTCQB: ALLM), today announced that it has signed a sublicense agreement with Phoenix Biomaterials Thomaston, LLC ("Phoenix") for the use of their licensed and patented CTS process, in a plant Phoenix intends to build in Thomaston, Georgia.
CTS 4345 ALLM
LISLE, Ill., April 03, 2018 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS) today announced that Alfonso G. Zulueta, President of Lilly International and Senior Vice President of Eli Lilly and Company, has been appointed to its board of directors, effective April 2, 2018.
Good morning. My name is Stephanie, and I will be your conference operator today. At this time, I would like to welcome everyone to the FactSet Second Quarter Earnings Call. All lines have been placed on mute to avoid any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.
CTS 4345 FDS TRI
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...